Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Account Payables (2017 - 2025)

Historic Change in Account Payables for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $3.0 million.

  • Dianthus Therapeutics' Change in Account Payables fell 4684.13% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 853.07%. This contributed to the annual value of $8.2 million for FY2024, which is 113918.31% up from last year.
  • Dianthus Therapeutics' Change in Account Payables amounted to $3.0 million in Q3 2025, which was down 4684.13% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Change in Account Payables ranged from a high of $5.7 million in Q3 2024 and a low of -$4.7 million during Q1 2023
  • Its 4-year average for Change in Account Payables is $842933.3, with a median of $1.4 million in 2022.
  • Per our database at Business Quant, Dianthus Therapeutics' Change in Account Payables tumbled by 43826.9% in 2023 and then soared by 63104.79% in 2024.
  • Dianthus Therapeutics' Change in Account Payables (Quarter) stood at -$339000.0 in 2022, then surged by 572.86% to $1.6 million in 2023, then skyrocketed by 42.23% to $2.3 million in 2024, then skyrocketed by 31.75% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $3.1 million for Q2 2025, and -$1.5 million during Q1 2025.